|
Delayed
Japan Exchange
23:44:15 2026-11-05 EST
|
5-day change | 1st Jan Change | ||
| 2,474.50 JPY | -7.41% |
|
-3.75% | +18.23% |
| 11-04 | Japanese Stocks Fall After Democrats Sweep US Midterm Elections; Oil Prices Rise | MT |
| 11-04 | Astellas Pharma Logs Higher Fiscal H1 Attributable Core Profit; Revenue Up | MT |
Company Valuation: Astellas Pharma Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,519,738 | 3,381,409 | 2,946,773 | 2,589,390 | 4,512,563 | 4,792,121 | - | - |
| Change | - | -3.93% | -12.85% | -12.13% | 74.27% | 6.2% | - | - |
| Enterprise Value (EV) 1 | 3,203,752 | 3,004,569 | 2,611,086 | 3,232,444 | 4,796,910 | 4,732,822 | 4,311,466 | 3,936,179 |
| Change | - | -6.22% | -13.1% | 23.8% | 48.4% | -1.34% | -8.9% | -8.7% |
| P/E | 28.5x | 34.7x | 173x | 51x | 15.5x | 12.2x | 13.2x | 17.1x |
| PBR | 2.39x | 2.24x | 1.85x | 1.71x | 2.47x | 2.29x | 2.08x | 1.97x |
| PEG | - | -1.8x | -2.1x | 0x | 0x | 0.4x | -1.75x | -0.7x |
| Capitalization / Revenue | 2.72x | 2.23x | 1.84x | 1.35x | 2.11x | 2.02x | 2.17x | 2.43x |
| EV / Revenue | 2.47x | 1.98x | 1.63x | 1.69x | 2.24x | 1.99x | 1.95x | 1.99x |
| EV / EBITDA | 13.6x | 12.6x | 14.2x | 13.5x | 8.31x | 6.23x | 6.09x | 6.53x |
| EV / EBIT | 20.6x | 22.6x | 102x | 78.8x | 12.5x | 9.28x | 9.03x | 10.6x |
| EV / FCF | 14.1x | 10.3x | -3.88x | 20.5x | 9.72x | 10.2x | 7.84x | 7.62x |
| FCF Yield | 7.08% | 9.7% | -25.8% | 4.87% | 10.3% | 9.78% | 12.7% | 13.1% |
| Dividend per Share 2 | 50 | 60 | 70 | 74 | 78 | 80.15 | 83.08 | 85.31 |
| Rate of return | 2.62% | 3.19% | 4.26% | 5.12% | 3.1% | 3% | 3.11% | 3.19% |
| EPS 2 | 67.08 | 54.24 | 9.51 | 28.35 | 162.8 | 219.5 | 203 | 156.5 |
| Distribution rate | 74.5% | 111% | 736% | 261% | 47.9% | 36.5% | 40.9% | 54.5% |
| Net sales 1 | 1,296,163 | 1,518,619 | 1,603,672 | 1,912,323 | 2,139,245 | 2,374,506 | 2,213,393 | 1,974,834 |
| EBITDA 1 | 235,370 | 238,767 | 183,358 | 240,171 | 577,227 | 759,330 | 707,826 | 602,722 |
| EBIT 1 | 155,686 | 133,029 | 25,518 | 41,039 | 382,633 | 510,043 | 477,613 | 371,935 |
| Net income 1 | 124,086 | 98,714 | 17,045 | 50,747 | 291,535 | 377,754 | 346,056 | 263,382 |
| Net Debt 1 | -315,986 | -376,840 | -335,687 | 643,054 | 284,347 | -59,299 | -480,654 | -855,942 |
| Reference price 2 | 1,911.00 | 1,883.00 | 1,643.50 | 1,446.50 | 2,519.00 | 2,672.50 | 2,672.50 | 2,672.50 |
| Nbr of stocks (in thousands) | 1,841,831 | 1,795,756 | 1,792,986 | 1,790,107 | 1,791,411 | 1,793,123 | - | - |
| Announcement Date | 4/27/22 | 4/27/23 | 4/25/24 | 4/25/25 | 4/27/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.39x | 1.86x | 5.83x | 3.21% | 28.3B | |
| 41.5x | 14.02x | 31.15x | 0.48% | 1,263B | |
| 40.44x | 6.79x | 19.1x | 1.93% | 665B | |
| 37.93x | 8.6x | 17.74x | 2.35% | 521B | |
| 21.34x | 5.18x | 12.9x | 2.53% | 387B | |
| 99.59x | 6.08x | 25.91x | 2.26% | 371B | |
| 23.46x | 6.01x | 14.51x | 2.66% | 310B | |
| 24.81x | 4.95x | 13.96x | 1.76% | 293B | |
| 29.96x | 7.59x | 13.11x | 2.11% | 259B | |
| -41.77x | 7.6x | 47.71x | 1.89% | 216B | |
| Average | 28.87x | 6.87x | 20.19x | 2.12% | 431.37B | |
| Weighted average by Cap. | 36.60x | 8.80x | 22.80x | 1.7% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4503 Stock
- Valuation Astellas Pharma Inc.
Select your edition
All financial news and data tailored to specific country editions
